Big Pharma Shouts, Generics And Biosimilars Whisper: M&A In 2023
Companies Sit On Dry Powder In Challenging M&A Market
“A lot of companies are hurting because of the higher interest rates,” one major CEO observed recently, summing up a year which saw little headline-grabbing news on the M&A front for generic and biosimilar sponsors.
